SYTL5

Across TCGA pan-cancer cohorts, SYTL5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SYTL5 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SYTL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYTL5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

COAD, LAML, and UCEC are the cancer types where SYTL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.082	0.871	<.001	33	view →
LAML	DFS	Median	All	0.112	0.582	.010	12	view →
UCEC	DFS	Median	II,III,IV	0.879	0.432	.027	8	view →
STAD	OS	Median	III,IV	1.000	0.367	.046	3	view →
SKCM	DFS	Median	II,III,IV	0.832	0.559	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SYTL5–COAD (OS)

Open the COAD breakdown →